Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer.

MLA

Salama, Joseph K., et al. “Phase I Study of Concomitant Chemoradiotherapy with Irinotecan, 5-FU, and Hydroxyurea for Patients with Advanced and/or Recurrent Head and Neck Cancer.” Cancer Journal (Sudbury, Mass.), vol. 11, no. 2, Mar. 2005, pp. 140–46. EBSCOhost, https://doi.org/10.1097/00130404-200503000-00009.

APA

Salama, J. K., Haraf, D. J., Stenson, K., Milano, M. T., Witt, M. E., & Vokes, E. E. (2005). Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer. Cancer Journal (Sudbury, Mass.), 11(2), 140–146. https://doi.org/10.1097/00130404-200503000-00009

Chicago

Salama, Joseph K, Daniel J Haraf, Kerstin Stenson, Michael T Milano, Mary Ellyn Witt, and Everett E Vokes. 2005. “Phase I Study of Concomitant Chemoradiotherapy with Irinotecan, 5-FU, and Hydroxyurea for Patients with Advanced and/or Recurrent Head and Neck Cancer.” Cancer Journal (Sudbury, Mass.) 11 (2): 140–46. doi:10.1097/00130404-200503000-00009.